[Pimaricin therapy in mycotic complications of hemoblastosis].
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007938:Leukemia / Q000150:complications; D008206:Lymphatic Diseases / Q000150:complications; D008297:Male; D008875:Middle Aged; D010866:Natamycin / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D009824:Ointments; D013280:Stomatitis / Q000188:drug therapy; D013488:Suppositories; D013607:Tablets; D013997:Time Factors; D014627:Vaginitis / Q000188:drug therapy
D000935:Antifungal Agents; D004338:Drug Combinations; D009824:Ointments; D013488:Suppositories; D013607:Tablets; D010866:Natamycin; D009355:Neomycin; D006854:Hydrocortisone
Pimaricin in der Therapie mykotischer Komplikationen bei Hämoblastosen.